Coya Therapeutics

COYAPhase 2

Houston, United Statescoyatherapeutics.com

Coya Therapeutics is pioneering a novel approach to treating chronic inflammatory diseases by targeting and enhancing the function of regulatory T cells (Tregs). The company has generated strong proof-of-concept data in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, with its lead biologic candidate, COYA 302, advancing in clinical trials for ALS and Frontotemporal Dementia (FTD). As a public, clinical-stage biotech, Coya is leveraging its multi-modality Treg platform to address significant unmet needs in large neurodegenerative and autoimmune markets.

Market Cap

$98.8M

Focus

Cell & Gene Therapy

COYA · Stock Price

USD 4.210.36 (-7.88%)

Historical price data

AI Company Overview

Technology Platform

A multi-modality platform focused on enhancing the function and number of regulatory T cells (Tregs) through biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapies to treat chronic inflammatory diseases.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage	Watch
COYA 302 + Placebo	Amyotrophic Lateral Sclerosis (ALS)	Phase 2

Funding History

Total raised: $55M

IPO$15MUndisclosedJan 26, 2023

Series A$30MLifesci VenturesJun 15, 2022

Seed$10MUndisclosedJun 15, 2021

Opportunities

The primary growth opportunity is the successful clinical development and approval of COYA 302 for ALS and FTD, which would validate the platform and open doors to expansion into other neurodegenerative and autoimmune indications.

The multi-modality approach allows for targeting different disease mechanisms and patient segments.

Risk Factors

Key risks include clinical trial failures for lead candidate COYA 302, the novel and unproven nature of Treg modulation in neurodegenerative diseases, dependence on future capital raises as a pre-revenue company, and increasing competition in the immuno-neurology space.

Competitive Landscape

Coya competes in the emerging field of Treg-targeting therapies with companies like Sangamo and Abata Therapeutics. Its key differentiation is the focus on combination biologics for neurodegenerative diseases and a multi-modality platform that includes exosomes and cell therapy, offering a broader therapeutic strategy.